ReviewDiscover nano2026
Cu-based metal-organic frameworks: synthesis, biomedical applications, and beyond.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Application Advances of Gold Nanoparticles in Cancer Theranostics: From Physicochemical Mechanisms to Multifunctional Nanoplatforms.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Copper-based metal organic frameworks (Cu-MOFs) represent a highly versatile family of porous crystalline materials valued for their tunable structures, redox-active Cu centers, and inherent biodegradability, which collectively increase their therapeutic and technological potential. This review provides an integrated overview of recent progress in synthetic approaches ranging from solvothermal and mechanochemical techniques to more sustainable, scalable green processes and emphasizes how precise control over coordination chemistry, defect formation, and surface engineering governs their physicochemical performance. Major biomedical advancements are highlighted, particularly their role as both drug delivery platforms and active therapeutic agents capable of generating reactive oxygen species for chemodynamic therapy, supporting synergistic phototherapies, and exerting antimicrobial effects, with innovations in stimuli-responsive designs and biomimetic modifications improving stability and targeting under physiological conditions. Additionally, the increasing importance of Cu-MOFs in catalysis, energy storage, and environmental remediation underscores their wide-ranging industrial significance. Nonetheless, challenges such as ensuring long-term biosafety, maintaining stability in biological environments, and achieving reproducible large-scale production continue to limit clinical translation. Future progress will rely on predictive design tools, deeper structure-function understanding, and standardized biological assessments. Overall, Cu-MOFs stand at the interface of materials science and biomedicine, with ongoing innovations poised to drive their evolution from promising laboratory systems into impactful real-world applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.